Drugs / Semorinemab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02820896 | Jun 2016 → Jun 2017 | Alzheimer disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03828747 | Jan 2019 → Jul 2021 | Alzheimer disease | Genentech, Inc. | Completed | Mixed |
| Phase 2 | NCT03289143 | Oct 2017 → Jan 2021 | Alzheimer disease | Genentech, Inc. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-11-10 | AC Immune SA | Results AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease acimmune.com ↗ |
| 2021-08-31 | AC Immune SA | Results AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease acimmune.com ↗
Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo (p<0.0025) as measured by the Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 11-item Version (ADAS-Cog11) at week 49 in people with mild-to-moderate AD (i.e., Mini-Mental State Examination (MMSE) 16-21). |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Semorinemab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03289143 ↗ |
| Known as | MTAU-9937A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298093 ↗ |
| Known as | RO7105705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02820896 ↗ |
| Action | Inhibit | “Microtubule-associated protein tau inhibitor” CHEMBL4298093 ↗ |
| Modality | Monoclonal antibody | “Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer's disease (AD).” PMID 39513754 ↗ Nov 2024 |
| Route | Subcutaneous | “Healthy participants will receive a single dose of RO7105705 SC on Day 1.” NCT02820896 ↗ |
| Target | MAPT | “Microtubule-associated protein tau inhibitor” CHEMBL4298093 ↗ |